US FDA approves 4DMedical’s lung imaging toolJune 10, 2020
4DMedical has received clearance from the US FDA to market its XV Technology, a patented four-dimensional lung imaging process that rapidly and automatically analyses any functional lung impairment from a single X-ray.
XV Technology process is a software-as-a-service (SaaS) diagnostic tool, available through secure cloud subscription, and can be implemented immediately, utilising existing hospital and clinical infrastructure with no capital expenditure or training required. Imaging departments simply electronically send an X-ray (using existing fluoroscopy equipment) to 4DMedical.
The software then automatically analyses and applies its proprietary algorithms to identify and quantify any functional impairment. The software generates a ventilation report and sends it to the hospital to enable clinicians to determine the most effective treatment course of action and allocation of finite hospital resources. The end-to-end process can be completed and a report generated within three hours.